Get started
Author

Sreekanth Gattu

Observed names: Gattu, Sreekanth, S Gattu, S. Gattu
Institution: Hexal (Germany)
ORCID: 0000-0003-2285-3701
Observed ORCID: 0000-0003-2285-3701
OpenAlex ID: A5036599126
Healthy donor hematopoietic stem cell mobilization with biosimilar granulocyte‐colony‐stimulating factor: safety, efficacy, and graft performance
2016 · Petra Becker, Arnd Schwebig, et al. · Transfusion · 33
Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy
2017 · K. Blackwell, P. Gascon, et al. · Annals of Oncology · 24
PDF
Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects
2018 · Roumen Nakov, Sreekanth Gattu, et al. · British Journal of Clinical Pharmacology · 20
PDF
Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies
2018 · Nadia Harbeck, Pere Gascón, et al. · The Oncologist · 13
PDF
A large multicentre, randomized, double‐blind, cross‐over study in healthy volunteers to compare pharmacokinetics, pharmacodynamics and safety of a pegfilgrastim biosimilar with its US‐ and EU‐reference biologics
2020 · Anne Bellon, Jessie Wang, et al. · British Journal of Clinical Pharmacology · 12
PDF
Safety Analysis of Proposed Pegfilgrastim Biosimilar In Phase I And Phase Iii Studies
2019 · Nadia Harbeck, Jessie Wang, et al. · Future Oncology · 7
PDF
Critical Factors Shaping Strategy Development of an Innovative Medicine in Oncology
2020 · Andriy Krendyukov, Sreekanth Gattu · Pharmaceutical Medicine · 6
Meta‐analysis of Pharmacokinetic/Pharmacodynamic Results of 3 Phase 1 Studies with Biosimilar Pegfilgrastim
2021 · Sreekanth Gattu, Jessie Wang, et al. · Clinical Pharmacology in Drug Development · 4
A review of the totality of evidence supporting the development and approval of a pegfilgrastim biosimilar (LA-EP2006)
2022 · Sanjiv S. Agarwala, Ulrich Nagl, et al. · Current Medical Research and Opinion · 3
PDF
Real-world perspective on career of pharmaceutical physicians in India: A working report (2018)
2019 · Sandeep Lahiry, Sreekanth Gattu · Perspectives in Clinical Research · 3
Career Planning for Physicians Within the Pharmaceutical Industry
2020 · Sandeep Lahiry, Sreekanth Gattu · Pharmaceutical Medicine · 2
Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim for the prevention of severe neutropenia, in patients with breast cancer receiving myelosuppressive chemotherapy.
2017 · Andriy Krendyukov, Nadia Harbeck, et al. · Journal of Clinical Oncology · 2
Patient-Reported Outcome Measures in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis Treated with GP2015, an Etanercept Biosimilar: Results from Two Phase III Studies (EGALITY and EQUIRA)
2025 · Diamant Thaçi, Sascha Gerdes, et al. · Drugs in R&D
PDF
A review of the totality of evidence supporting the development and approval of a pegfilgrastim biosimilar (LA-EP2006)
2022 · Agarwala, Sanjiv S., Nagl, Ulrich, et al. · Figshare
Abstract P5-14-16: Pharmacokinetics/pharmacodynamics of Sandoz biosimilar pegfilgrastim compared to both US- and EU-reference pegfilgrastim: A meta-analysis of three clinical studies in healthy subjects
2020 · Roumen Nakov, Jessie Wang, et al. · Cancer Research
Pf353 Patients With Severe Chronic Neutropenia Subtypes Treated With Biosimilar Filgrastim: a Study by the European Branch of the Severe Chronic Neutropenia International Registry
2019 · C. Zeidler, S. Mellor‐Heineke, et al. · HemaSphere
Abstract P4-16-14: Meta-analysis of Phase I pharmacokinetic/pharmacodynamic results of proposed biosimilar pegfilgrastim
2019 · R Nakov, J Wang, et al. · Cancer Research
Abstract P3-14-10: Proposed biosimilar pegfilgrastim LA-EP2006 shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects
2018 · R Nakov, S Gattu, et al. · Cancer Research
Safety profile of EP2006 biosimilar filgrastim: A combined analysis of two independent phase III studies.
2017 · Nadia Harbeck, Pedro Gascon, et al. · Journal of Clinical Oncology
Works count: 19
Citation count: 129
H-index: 6
I10-index: 5
Year
Topic
Type